Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Anticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 3,017
NF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
“As such, cyclin D1-deficient mice are resistant to developing mammary cancers and squamous tumours that are induced by the HRAS oncogen”
BackgroundThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“Moreover, whereas mice overexpressing Her2/Neu or oncogenic Ras transgenes targeted to mammary epithelium rapidly develop breast cancer, they fail to do so in a cyclin D1 null background, indicating that D1 function is essential for tumorigenesis and that other D-type cyclins in breast tissue cannot compensate (Yu et…”
BackgroundInfluentialTo cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
“In addition, a pivotal role for cyclin D1 function in HER2-mediated transformation has been described using transgenic mouse models [43].”
BackgroundCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“Cells lacking all three D-type cyclins are resistant to transformation by various oncogenes in vitro , and mice lacking cyclin D1 are resistant to the effects of some, although not all, mammary oncogene”
BackgroundMammalian cyclin-dependent kinases
Malumbres, M., & Barbacid, M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.09.005 · Cited by 1,295
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
“MMTV-neu mice have almost complete protection from tumor formation in a cyclin D1-null background (Lee et al., 2000; Yu et al., 2001).”
BackgroundG1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
NF-kB in development and progression of human cancer
Dolcet, X., Llobet, D., Pallares, J., & Matias-Guiu, X. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1264-9 · Cited by 1,169
“NF-kB-induced cyclin D1 expression appears to be a key element in mammary gland development and breast carcinogenesis [73].”
BackgroundTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
“Similarly, cyclin D1 inactivation confers resistance to breast cancers induced by oncogenic Neu or Ras transgenes targeted to the mammary gland (Yu et al. 2001) and to intestinal tumors resulting from Apc loss and constitutive -catenin signaling (Hulit et al.”
BackgroundCyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
“Mammary hyperplasia and carcinoma occur in mouse mammary tumor virus (MMTV) –cyclin D1 transgenic mice,(37,38) and cyclin D1 is a critical mediator of breast cancer induction by Ras or Neu oncogenes, given that MMTV-v-Ha-ras and MMTV-c-neu transgenic mice are protected from breast cancer in a cyclin D1 knockout backgr…”
BackgroundCyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Self-citationMinireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
“Tissue culture-based experiments evidenced cyclin D1 functions as a collaborative oncogene that enhances oncogenic transformation of other oncogenes (i.e. Ras, Src, E1A) in cultured cells (22, 90–92).”
BackgroundInfluentialTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Alao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871
“These studies indicate that the induction of cyclin D1 degradation may offer a useful avenue for therapeutic intervention [25-32].”
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
“In mouse models of ER-positive breast cancer, cyclin D1 is required for oncogenesis (5).”
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease
Lu, K. P., & Zhou, X. Z. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2261 · Cited by 682
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
Mammalian G1- and S-phase checkpoints in response to DNA damage
Bartek, J., & Lukas, J. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00280-5 · Cited by 573
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Notch Signaling in Development and Cancer
Bolós, V., Grego-Bessa, J., & de la Pompa, J. L. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0046 · Cited by 545
Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform
Mulac-Jericevic, B., Lydon, J. P., DeMayo, F. J., & Conneely, O. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732707100 · Cited by 547
The Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
“Recently, Sicinski and colleagues (157) reported that this regulator was critical for v-Ha-ras- and c-neu-, but not c-myc- and Wnt-1-, induced carcinogenesis in transgenic models.”
BackgroundOncogenes and Tumor Suppressor Genes
Lee, E. Y. H. P., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 508
“Germ-line loss of cyclin D1 in the MMTV/ErbB2 transgenic strains results in a complete block in tumor progression (Yu et al. 2001).”
BackgroundCyclin E in normal and neoplastic cell cycles
Hwang, H. C., & Clurman, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208613 · Cited by 514
“Finally, reminiscent of previous studies from the Sicinski lab indicating that cyclin D1 ablation renders mammary epithelial cells resistant to transformation by Ras (Yu et al., 2001), cyclin E-null MEFs are resistant to oncogenic transformation in vitro.”
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
“Hyperactivation of the D-type cyclin–CDK4/6 axis in cancer cells has been observed in many preclinical studies, particularly in the context of breast cancer [53,54], making its targeted inhibition an attractive anticancer strategy.”
BackgroundMontalto, F. I., & De Amicis, F. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 496
“Further data establish that Cyclin D1 is important for the development of mammary cancers induced by different oncoproteins such as receptor tyrosine-protein kinase erbB-2 (Her2/neu) [13] and v-Ha-ras, but not those induced by c-Myc or Wnt-1 [14].”
BackgroundCDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript The RAS-RAF-MEK-ERK signaling pathway also enhances CDK4/6 activity by driving CCND1 transcription (Figure 3).”
BackgroundInfluentialSpring, L. M., Wander, S. A., Andre, F., Moy, B., Turner, N. C., & Bardia, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30165-3 · Cited by 468
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
Self-citationCao, Y., Bonizzi, G., Seagroves, T. N., Greten, F. R., Johnson, R., Schmidt, E. V., & Karin, M. (2001) · Cell · doi:10.1016/s0092-8674(01)00599-2 · Cited by 482
DNA damage checkpoint control in cells exposed to ionizing radiation
Iliakis, G., Wang, Y., Guan, J., & Wang, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206682 · Cited by 476
“…of CDK2 by this pathway is thought to reflect redistribution of the P21 CDK inhibitor (see below) from the CDK4-Cyclin D1 complex, where it serves as an assembly factor, to cyclin E-CDK2 complexes, which are inhibited by P21 (Sherr and Roberts, 1999; Agami and Bernards, 2000; Yu et al., 2001).”
BackgroundOvercoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
“Indeed, cyclin D1 is required for the formation and maintenance of these tumors (Choi et al., 2012; Yu et al., 2001).”
Cyclins and cdks in development and cancer: a perspective
Deshpande, A., Sicinski, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 464
“Likewise, expression of cyclin E1 in place of cyclin D1 ‘corrected’ the resistance of cyclin D1-null mice to c-Erb-2-driven mammary tumor formation (Yu et al., 2001).”
BackgroundAnczuków, O., Rosenberg, A. Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S. K., & Krainer, A. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2207 · Cited by 447
Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 437
DNA damage checkpoints in mammals
Niida, H., & Nakanishi, M. (2006) · Mutagenesis · doi:10.1093/mutage/gei063 · Cited by 432
“The reduced cyclin D1 protein then decreases the amount of cyclin D1–Cdk4 complex, resulting in the redistribution of p21CKI to cyclin E–Cdk2 and the inhibition of cyclin E–Cdk2 (91,92).”
BackgroundRequirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Self-citationMaitra, A., Adsay, N. V., Argani, P., Iacobuzio-Donahue, C., De Marzo, A., Cameron, J. L., Yeo, C. J., & Hruban, R. H. (2003) · Modern Pathology · doi:10.1097/01.mp.0000086072.56290.fb · Cited by 429
“Overexpression of cyclin D1 protein has been documented in several human cancers, such as breast, lung, and colon carcinoma, and in mantle cell lymphoma (”
BackgroundLinking cyclins to transcriptional control
Coqueret, O. (2002) · Gene · doi:10.1016/s0378-1119(02)01055-7 · Cited by 431
Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression
Liu, M.-M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., & Kushner, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201829200 · Cited by 422
Signaling Pathways in Mammary Gland Development
Hennighausen, L., & Robinson, G. W. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00064-8 · Cited by 422
Nuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413
“Additional work using mice wherein endogenous CDK4 was deleted via homologous recombination also reported resistance to mammary tumorigenesis (Reddy et al., 296 K I M A N D D I E H L 2005; Yu et al., 2006).”
BackgroundBulavin, D. V., Phillips, C., Nannenga, B., Timofeev, O., Donehower, L. A., Anderson, C. W., Appella, E., & Fornace, A. J. (2004) · Nature Genetics · doi:10.1038/ng1317 · Cited by 409
The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer
Greten, F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.029 · Cited by 410
“[23] Q.”
BackgroundCyclin D1 in Breast Cancer Pathogenesis
Arnold, A., & Papanikolaou, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.064 · Cited by 411
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation
Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., & White, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4309-4318.2002 · Cited by 393
“Presumably, the cyclin D1 / MEFS have bypassed the requirement for cyclin D1 expression through developmental compensation (14, 40).”
BackgroundAnti cancer effects of curcumin: cycle of life and death
Sa, G., & Das, T. (2008) · Cell Division · doi:10.1186/1747-1028-3-14 · Cited by 382
“In normal cells cyclin D1 expression is tightly regulated by mitogenic signals involving Ras pathway [17].”
BackgroundTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
“refractory to Notch1-driven T cell acute lymphoblastic leukemia [7, 46, 47].”
BackgroundSignaling Pathways that Control Cell Proliferation
Duronio, R. J., & Xiong, Y. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008904 · Cited by 372
“Mice transgenically expressing cyclin D1 develop mammary gland tumors and conversely are protected against mammary tumors if cyclin D1 is deleted (Wang et al. 1994; Yu et al. 2001).”
BackgroundXu, X.-R., Huang, J., Xu, Z.-G., Qian, B.-Z., Zhu, Z.-D., Yan, Q., Cai, T., Zhang, X., Xiao, H.-S., Qu, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241522398 · Cited by 365
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation
Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M. C., Liu, M., Wu, K., Whittle, J., Ju, X., Hyslop, T., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801079 · Cited by 363
“Cyclin D1 is required for ErbB2-induced mammary tumorigenesis in vivo ( Lee et al., 2000 ; Yu et al., 2001 ).”
Targeting cell cycle regulation in cancer therapy
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361
Cancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
“…growth (Coussens et al., 2000).tumorigenesis, it was dispensable for Ras-induced skin These experiments further emphasize that studies intumors (Yu et al., 2001, and references therein). mice in which every cell has the same alteration, as inAlthough much has been learned about the early…”
BackgroundThe Molecular Mechanism Governing the Oncogenic Potential of SOX2 in Breast Cancer
Chen, Y., Shi, L., Zhang, L., Li, R., Liang, J., Yu, W., Sun, L., Yang, X., Wang, Y., Zhang, Y., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802917200 · Cited by 358
RAS and RHO GTPases in G1-phase cell-cycle regulation
Coleman, M. L., Marshall, C. J., & Olson, M. F. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1365 · Cited by 355
“The crucial importance of cyclin D1 for RAS-induced cell proliferation is shown by the resistance of mice that lack cyclin D1 to the induction of breast cancer by oncogenic H-Ras in mammary epithelial cell”
BackgroundMukhopadhyay, A., Banerjee, S., Stafford, L. J., Xia, C., Liu, M., & Aggarwal, B. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206048 · Cited by 353
“The genetic deletion of cyclin D1 in mice impaired breast development during pregnancy (Sicinski and Weinberg, 1997; Fantl et al., 1995, 2000; Yu et al., 2001), and these mice were found resistant to breast cancers induced by ras, rac and neu oncogenes (Albanese et al., 1995; Joyce et al., 1999;…”
BackgroundHER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 348
Pinning down proline-directed phosphorylation signaling
Lu, K. P., Liou, Y.-C., & Zhou, X. Z. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02253-5 · Cited by 349
Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity
Cao, J., Schulte, J., Knight, A., Leslie, N. R., Zagozdzon, A., Bronson, R., Manevich, Y., Beeson, C., & Neumann, C. A. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.101 · Cited by 344
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
“Female MMTV-ErbB2 mice develop mammary adenocarcinomas with a median latency of 30–40 weeks (Yu et al., 2001).”
BackgroundInfluentialRequirement for cyclin D3 in lymphocyte development and T cell leukemias
Sicinska, E., Aifantis, I., Le Cam, L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 340
Self-citationMalumbres, M., & Barbacid, M. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.008 · Cited by 338
Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes
Liou, Y.-C., Ryo, A., Huang, H.-K., Lu, P.-J., Bronson, R., Fujimori, F., Uchida, T., Hunter, T., & Lu, K. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032404099 · Cited by 339
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., & Lupu, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403390101 · Cited by 327
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy
Tolomeo, M., & Cascio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020603 · Cited by 318
“Furthermore, cyclin D1-deficient animals are resistant to Rasand Neu-mediated skin and breast tumorigenesis [58,59].”
BackgroundAn autocrine mechanism for constitutive Wnt pathway activation in human cancer cells
Bafico, A., Liu, G., Goldin, L., Harris, V., & Aaronson, S. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.032 · Cited by 324
“To assess the effects of Wnt autocrine inhibition in vivo, we performed cyclin D1 is unlikely to be a critical Wnt target (Yu et al., 2001; Rowlands et al., 2003).”
MethodChoudhuri, T., Pal, S., Das, T., & Sa, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410670200 · Cited by 321
Razandi, M., Alton, G., Pedram, A., Ghonshani, S., Webb, P., & Levin, E. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1633-1646.2003 · Cited by 323
“It has also been recently reported that specifically cyclin D1 is essential to the development of rodent breast cancer, resulting from Ras or Neu oncogene signaling (51).”
BackgroundCDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316
Julien, S. G., Dubé, N., Read, M., Penney, J., Paquet, M., Han, Y., Kennedy, B. P., Muller, W. J., & Tremblay, M. L. (2007) · Nature Genetics · doi:10.1038/ng1963 · Cited by 316
Sun, C., Li, S., Zhang, F., Xi, Y., Wang, L., Bi, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10108 · Cited by 312
Eeckhoute, J., Carroll, J. S., Geistlinger, T. R., Torres-Arzayus, M. I., & Brown, M. (2006) · Genes & Development · doi:10.1101/gad.1446006 · Cited by 304
“CCND1 oncogenic activity in the mam- mary gland was confirmed by genetically modified mouse models where CCND1 overexpression leads to the development of mammary carcinoma (Wang et al. 1994), while CCND1 ablation results in mice resistant to cancer induced by several oncogenes (Yu et al. 2001).”
BackgroundWiseman, B. S., Sternlicht, M. D., Lund, L. R., Alexander, C. M., Mott, J., Bissell, M. J., Soloway, P., Itohara, S., & Werb, Z. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302090 · Cited by 303
“At least part of the function of the MMPs is to activate TGF-β, which inhibits lateral branching (Bottinger et al., 1997; Yu et al., 2001; Ewan et al., 2002).”
BackgroundJanssen, K., Alberici, P., Fsihi, H., Gaspar, C., Breukel, C., Franken, P., Rosty, C., Abal, M., El Marjou, F., Smits, R., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.011 · Cited by 298
Conditional mouse models of sporadic cancer
Jonkers, J., & Berns, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc777 · Cited by 294
“cgi?l=595">cyclin D1 loss on mammary tumorigenesis in oncogene-bearing transgenic mic”
BackgroundThe regulation of protein phosphorylation
Johnson, L. N. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370627 · Cited by 291
Coordinated regulation of life and death by RB
Chau, B. N., & Wang, J. Y. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc993 · Cited by 292
“, and cyclin-D1-null mice are resistant to mammary tumour development induced by the murine mammary tumour viru”
Backgroundp38 MAP Kinase's Emerging Role as a Tumor Suppressor
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)92005-2 · Cited by 290
Rho GTPases: functions and association with cancer
Ellenbroek, S. I. J., & Collard, J. G. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9119-1 · Cited by 289
“Considering the effects of Rho GTPases on cell cycle progression through cyclin D1, it is of interest that breast cancer mouse models revealed that the Neu- and Rasoncogenic pathways are dependent on cyclin D1 whereas c-myc and Wnt-1 oncogenic pathways are not [132].”
BackgroundLeslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y. B., Paz, K., Darnell, J. E., Albanese, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2203 · Cited by 285
“In contrast, immortalized MEFs from cyclin D1–deficient mice were fully transformed by the neu and ras oncogenes (19).”
InfluentialSignaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“Indeed, cyclin D1deficient mice are resistant to MMTV-ErbB2- and MMTV-Ras-induced breast cancers [106].”
BackgroundTranscriptional role of cyclin D1 in development revealed by a genetic-proteomic screen
Bienvenu, F., Jirawatnotai, S., Elias, J. E., Meyer, C. A., Mizeracka, K., Marson, A., Frampton, G. M., Cole, M. F., Odom, D. T., Odajima, J., et al. (2010) · Nature · doi:10.1038/nature08684 · Cited by 276
Self-citationCyclin D1 is a candidate oncogene in cutaneous melanoma.
Sauter, E. R., Yeo, U. C., von Stemm, A., Zhu, W., Litwin, S., Tichansky, D. S., Pistritto, G., Nesbit, M., Pinkel, D., Herlyn, M., et al. (2002) · PubMed · Cited by 334
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.